2025-11-20 – Press Releases – www.prnewswire.com
IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ — PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced that two abstracts from its ongoing Phase 1 studies of PMB-CT01 (BAFFR-CAR T) have been…
